NCT02625558Unknown4 期
A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Time until clinical worsening
研究概览
简要总结
Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension
详细描述
Study design Patients will be recruited into double blind randomized trial of riociguat with 1:1 active drug to placebo. The table below summarizes the study design. Patients will have previously undergone right heart catheterization (RHC) within six months of initial dose dispensation and with no significant change in treatment for pulmonary hypertension. Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day.
The patient will be treated for 48 weeks or until clinical worsening of disease. An adjudication committee will review all cases of clinical worsening. This committee will be blinded to treatment. The determination by the adjudication committee will be used as the final determinant for the primary end point.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosis of sarcoidosis
- •Age ≥ 18 years.
- •Life expectancy of at least 2 years.
- •Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
- •Females of reproductive potential (FRP) must have a negative, pre-treatment pregnancy test.
- •FRP must obtain monthly pregnancy tests during treatment and one month after treatment discontinuation. Post-menopausal women (defined as no menses for at least 1 year or post-surgical from bilateral oophorectomy) and surgically sterilized women are not required to undergo a pregnancy test.
- •Females of reproductive potential and all non-vasectomized male participants must agree to use reliable contraception when sexually active.
- •Subjects (males and females) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug.
- •Willing and able to comply with the protocol, including follow-up visits and examinations
排除标准
- •Patients with an FVC of less than 30% of predicted during screening visit.
- •Patients with severe airway obstruction
- •Patients unable to perform the 6 minute walk test
- •Pregnant women (i.e. positive serum ß-human chorionic gonadotropin test or other signs of pregnancy),
- •Breast feeding women
- •FRP not using reliable contraception as recommended in the Prescriber Guide for the riociguat pregnancy monitoring program
- •Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
- •Known significant left heart disease:
- •Pulmonary venous hypertension indicated by baseline pulmonary capillary wedge pressure > 15 mmHg
- •Active state or history of hemoptysis or pulmonary hemorrhage
- •Subjects requiring nitrates for any reason
- •Subject using nitrates within one month of entering study
- •Pulmonary veno-occlusive disease
- •Subjects with underlying medical disorders with an anticipated life expectancy below 2 years (e.g. active cancer disease with localized and/or metastasized tumor).
- •Subjects with hypersensitivity to the investigational drug or any of the excipients.
- •Women who are pregnant or breast-feeding.
- •Severe proven or suspected coronary artery disease
- •Clinical relevant hepatic dysfunction indicated by: bilirubin >2 times upper limit normal at Visit 0 and/or: alanine aminotransferase (ALT) or AST aspartate aminotransferase (AST) >3 times upper limit normal at Visit 0 and/or: signs of severe hepatic insufficiency (e.g. impaired albumin synthesis with an albumin <32 g/L, hepatic encephalopathy > grade 1a) at Visit 0
- •West Haven Criteria of Altered Mental Status in Hepatic Encephalopathy
- •Severe renal insufficiency indicated by a glomerular filtration rate <30 mL/min at Visit 0, e.g. calculated based on the Cockcroft formula or the Modification of Diet in Renal Disease Study Group (MDRD) formula
- •Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
- •Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
- •Excluded therapies and medications, previous and concomitant
- •Specific (e.g. sildenafil or tadalafil) or unspecific phosphodiesterase inhibitors (e.g. dipyridamole, theophylline).
- •NO donors (e.g. nitrates). Single applications of vasoactive drugs in connection with diagnostic vasoreactive testing are allowed.
- •Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form).
- •Major surgery within 30 days prior to start of study drug.
研究组 & 干预措施
Riociguat
Active Comparator
Active drug
干预措施: Riociguat (Drug)
Placebo
Placebo Comparator
placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Time until clinical worsening
时间窗: 48 weeks
Patient shows deterioration using fixed criteria
次要结局
- Pulmonary function(48 weeks)
- Quality of life(48 weeks)
- Safety: adverse events(48 weeks)
- Six minute walk(48 weeks)
研究者
Robert P Baughman
Professor
University of Cincinnati
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Inhaled Iloprost for Sarcoidosis-associated Pulmonary HypertensionPulmonary Arterial HypertensionSarcoidosisNCT00403650University of Cincinnati20
Unknown
3 期
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary SarcoidosisPulmonary SarcoidosisNCT05247554Assistance Publique - Hôpitaux de Paris200
已完成
2 期
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionPulmonary Arterial HypertensionSarcoidosisNCT00581607University of Cincinnati43
已完成
不适用
Sarcoidosis-associated Pulmonary HypertensionSARCOIDOSISNCT01139710Meir Medical Center75
已完成
2 期
Tadalafil for Sarcoidosis Associated Pulmonary HypertensionPulmonary HypertensionNCT01324999University of North Carolina, Chapel Hill12